SPRIX (ketorolac nasal spray)

SPRIX (ketorolac nasal spray)

SELF-ADMINISTRATION - NASAL

Indications for Prior Authorization

• Indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.

Patient must meet the following criteria for the indication(s) above:

• The patient is being treated for acute pain, AND
• The patient experienced an inadequate treatment response or intolerance to an oral generic ketorolac product OR the patient is unable to swallow oral medications, AND
• The patient will be treated for less than or equal to 5 days

Dosing:

• The total duration or use of Sprix® alone or sequentially with other formulations of ketorolac (IM/IV or oral) must not exceed 5 days due to the potential for increasing the frequency and severity of adverse reactions associated with the recommended doses.
• Sprix® cannot be used concomitantly with other formulations of ketorolac or other NSAIDs.

Approval:

• 5 days maximum supply.